Mankind Pharma reported strong Q2 FY27 results with revenue reaching Rs 4,338 crore, a 17% increase YoY. Profit after tax rose 37.7% to Rs 716 crore, bolstered by margin expansion to 27.1%. While the core chronic and international segments delivered robust growth, the company noted softness in its consumer healthcare division. Management remains focused on long-term expansion in the chronic therapy market and integration of its new CAR-T cell therapy platform.
Mankind Pharma Q2 FY27: Profit Up 37.7% to Rs 716 Crore
Revenue at Rs 4,338 crore (+17% YoY) and EBITDA at Rs 1,175 crore (+27.2% YoY).
Reader Takeaway: Strong chronic segment and international growth drive double-digit gains, though consumer healthcare remains a drag.
What just happened
Mankind Pharma delivered a strong financial performance for the second quarter of FY27. The company's revenue from operations climbed 17% year-on-year to Rs 4,338 crore. Profit after tax saw a significant jump of 37.7% to Rs 716 crore. EBITDA margins expanded by 210 basis points to 27.1%, aided by better gross margins and operational efficiencies.
Why this matters
The results highlight the company's successful pivot toward the high-margin chronic segment, where its market share reached 37.4%. The international business continues to be a major growth engine, posting 33% revenue growth. While the consumer healthcare business faced headwinds with slower industry offtake, the core pharma segments outperformed the industry, validating the company's focus on specialty therapies.
Strategic Developments
Mankind Pharma has entered the high-tech space by acquiring Armed Cell Therapeutics to access a CAR-T cell therapy platform. Additionally, the company received a tax relief order from the Commissioner of Appeals, reducing legal tax exposure by Rs 300 crore. Its R&D asset, a JAK inhibitor, also received government funding under the PRIP program.
Risks to watch
Investors should closely track the consumer healthcare recovery, which management expects to remain sluggish until FY28. Operating working capital increased to 51 days, up from 46 days, signaling a need to watch cash flow cycles. Increased R&D spending, driven by new acquisitions, could also exert pressure on short-term costs.
What to track next
Watch for the recovery trajectory of the consumer healthcare division and progress on the CAR-T therapy integration. Management maintains margin guidance of 25.5-26.5% for the fiscal year, and investors will look for consistency in the company's ability to maintain its 100-200 bps annual growth in chronic market share.